(Reuters) – The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical’s therapy to treat a rare genetic blood disorder in adult and pediatric patients.
(Reporting by Khushi Mandowara and Vaibhav Sadhamta in Bengaluru; Editing by Shounak Dasgupta)
